卡培他滨单药治疗转移性非胰腺神经内分泌肿瘤的 II 期研究。
Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours.
机构信息
University Department of Medical Oncology, Cancer and Haematology Centre, Churchill Hospital, Headington OX3 7LJ, UK.
出版信息
Br J Cancer. 2011 Mar 29;104(7):1067-70. doi: 10.1038/bjc.2011.76. Epub 2011 Mar 8.
Abstract
BACKGROUND
This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic neuroendocrine tumours (NETs).
METHODS
Multicentre phase II, first-line study design. Oral capecitabine was administered on days 1-14 of 3-week cycles.
RESULTS
Treatment was safe and well tolerated. Common toxicities were diarrhoea and fatigue.
CONCLUSION
The study provides evidence to support the use of capecitabine as a substitute for infusional 5FU in the management of NETs.
摘要
背景
本研究旨在确定单药卡培他滨（5FU 的前体药物）在转移性非胰腺神经内分泌肿瘤（NETs）患者中的安全性。
方法
多中心、二期、一线研究设计。卡培他滨在每 3 周的周期中第 1-14 天口服给药。
结果
治疗安全且耐受良好。常见的毒性反应是腹泻和疲劳。
结论
该研究为卡培他滨替代 5FU 输注用于 NETs 治疗提供了证据。
相似文献
1
Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours.卡培他滨单药治疗转移性非胰腺神经内分泌肿瘤的 II 期研究。
Br J Cancer. 2011 Mar 29;104(7):1067-70. doi: 10.1038/bjc.2011.76. Epub 2011 Mar 8.
2
Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda) monotherapy.
Cancer Chemother Pharmacol. 2008 Feb;61(2):347-8. doi: 10.1007/s00280-007-0590-9. Epub 2007 Sep 25.
3
Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours.177Lu-奥曲肽联合卡培他滨治疗7例胃肠胰神经内分泌肿瘤的短期副作用报告
Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):743-8. doi: 10.1007/s00259-007-0688-7. Epub 2008 Jan 11.
4
A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG.一项比较聚乙二醇化脂质体阿霉素与卡培他滨作为老年转移性乳腺癌患者一线化疗方案的随机III期研究：荷兰乳腺癌研究组BOOG的OMEGA研究结果
Ann Oncol. 2014 Mar;25(3):599-605. doi: 10.1093/annonc/mdt588. Epub 2014 Feb 6.
5
Capecitabine plus rofecoxib show no activity in patients with metastatic neuroendocrine tumours.
Clin Oncol (R Coll Radiol). 2006 Feb;18(1):88-9. doi: 10.1016/j.clon.2005.08.012.
6
A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.一项关于卡培他滨/替莫唑胺（CAPTEM）方案治疗既往治疗失败的转移性胰腺神经内分泌肿瘤（pNETs）的回顾性研究。
JOP. 2013 Sep 10;14(5):498-501. doi: 10.6092/1590-8577/1589.
7
Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.贝伐珠单抗联合卡培他滨治疗胃肠道（GI-NETs）进展期高分化神经内分泌肿瘤患者（BETTER 试验）——一项 II 期非随机试验。
Eur J Cancer. 2014 Dec;50(18):3107-15. doi: 10.1016/j.ejca.2014.10.001. Epub 2014 Oct 18.
8
Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma.卡培他滨单药治疗转移性肾细胞癌患者的II期研究。
Urol Oncol. 2006 Nov-Dec;24(6):487-91. doi: 10.1016/j.urolonc.2006.03.004.
9
Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.放射性核素 177Lu-奥曲肽与卡培他滨治疗进展性播散性神经内分泌肿瘤的 II 期研究。
Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):302-11. doi: 10.1007/s00259-010-1631-x. Epub 2010 Oct 30.
10
Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer.口服卡培他滨用于晚期或转移性胰腺癌患者的II期研究。
J Clin Oncol. 2002 Jan 1;20(1):160-4. doi: 10.1200/JCO.2002.20.1.160.
引用本文的文献
1
Progress in the Treatment of Small Intestine Cancer.小肠癌治疗进展
Curr Treat Options Oncol. 2023 Apr;24(4):241-261. doi: 10.1007/s11864-023-01058-3. Epub 2023 Feb 24.
2
Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review.高分化神经内分泌肿瘤（NET）G1、G2和G3的化疗：一项叙述性综述
J Clin Med. 2023 Jan 16;12(2):717. doi: 10.3390/jcm12020717.
3
Metronomic chemotherapy in patients with advanced neuroendocrine tumors: A single-center retrospective analysis.节拍化疗治疗晚期神经内分泌肿瘤患者：单中心回顾性分析。
J Neuroendocrinol. 2022 Oct;34(10):e13189. doi: 10.1111/jne.13189. Epub 2022 Aug 16.
4
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).替莫唑胺或替莫唑胺联合卡培他滨治疗晚期胰腺神经内分泌肿瘤的随机研究（ECOG-ACRIN E2211）。
J Clin Oncol. 2023 Mar 1;41(7):1359-1369. doi: 10.1200/JCO.22.01013. Epub 2022 Oct 19.
5
Chemotherapy in NEN: still has a role?神经内分泌肿瘤的化疗：仍有作用？
Rev Endocr Metab Disord. 2021 Sep;22(3):595-614. doi: 10.1007/s11154-021-09638-0. Epub 2021 Apr 11.
6
Medical Management of Gastroenteropancreatic Neuroendocrine Tumors.胃肠胰神经内分泌肿瘤的医学管理
Surg Oncol Clin N Am. 2020 Apr;29(2):293-316. doi: 10.1016/j.soc.2019.11.004.
7
Management of Gastrointestinal Neuroendocrine Tumors.胃肠道神经内分泌肿瘤的管理
Clin Med Insights Endocrinol Diabetes. 2019 Oct 24;12:1179551419884058. doi: 10.1177/1179551419884058. eCollection 2019.
8
Management of Small Bowel Neuroendocrine Tumors.小肠神经内分泌肿瘤的管理
Cancers (Basel). 2019 Sep 18;11(9):1395. doi: 10.3390/cancers11091395.
9
Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis.卡培他滨联合替莫唑胺（CAPTEM）治疗晚期神经内分泌肿瘤的安全性和有效性：一项荟萃分析。
Medicine (Baltimore). 2018 Oct;97(41):e12784. doi: 10.1097/MD.0000000000012784.
10
Where are we with treatment options after first line in small cell lung cancer?-report of two opposite cases treated with CAPTEM regimen and possible perspectives.小细胞肺癌一线治疗后我们在治疗选择方面处于什么情况？——两例接受CAPTEM方案治疗的相反病例报告及可能的前景。
J Thorac Dis. 2018 Jul;10(7):E520-E525. doi: 10.21037/jtd.2018.06.44.
本文引用的文献
1
Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin.胃肠胰神经内分泌肿瘤的系统治疗。
Endocr Relat Cancer. 2010 Jan 29;17(1):R75-90. doi: 10.1677/ERC-09-0108. Print 2010 Mar.
2
Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network.晚期高分化神经内分泌癌中持续氟尿嘧啶输注联合奥曲肽长效制剂：皮埃蒙特大区肿瘤网络的 II 期试验。
BMC Cancer. 2009 Nov 3;9:388. doi: 10.1186/1471-2407-9-388.
3
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.奥曲肽长效注射剂（LAR）对转移性中肠神经内分泌肿瘤患者肿瘤生长控制效果的安慰剂对照、双盲、前瞻性、随机研究：PROMID研究组报告
J Clin Oncol. 2009 Oct 1;27(28):4656-63. doi: 10.1200/JCO.2009.22.8510. Epub 2009 Aug 24.
4
NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors.美国国立综合癌症网络（NCCN）肿瘤学临床实践指南：神经内分泌肿瘤
J Natl Compr Canc Netw. 2009 Jul;7(7):712-47. doi: 10.6004/jnccn.2009.0050.
5
Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up.神经内分泌胃肠胰腺肿瘤：ESMO关于诊断、治疗及随访的临床建议
Ann Oncol. 2009 May;20 Suppl 4:150-3. doi: 10.1093/annonc/mdp158.
6
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.“类癌”百年之后：美国35825例神经内分泌肿瘤的流行病学及预后因素
J Clin Oncol. 2008 Jun 20;26(18):3063-72. doi: 10.1200/JCO.2007.15.4377.
7
Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors.胸苷酸合成酶在胃肠胰和肺神经内分泌肿瘤中的表达
Clin Cancer Res. 2008 Feb 15;14(4):1059-64. doi: 10.1158/1078-0432.CCR-07-1513.
8
Gastroenteropancreatic neuroendocrine tumours.胃肠胰神经内分泌肿瘤
Lancet Oncol. 2008 Jan;9(1):61-72. doi: 10.1016/S1470-2045(07)70410-2.
9
Diagnosis and treatment of gastric neuroendocrine tumours.胃神经内分泌肿瘤的诊断与治疗
Wien Klin Wochenschr. 2007;119(19-20):570-2. doi: 10.1007/s00508-007-0879-z.
10
Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review.卡培他滨与持续输注5-氟尿嘧啶用于直肠癌新辅助治疗的回顾性研究
Int J Colorectal Dis. 2008 Feb;23(2):139-45. doi: 10.1007/s00384-007-0382-z. Epub 2007 Oct 2.
Zotero 插件